Navigation Links
Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
Date:2/5/2013

HAYWARD, Calif., Feb. 5, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Owen Hughes, Jr. , to the position of Chief Business Officer (CBO) and Head of Corporate Development. Mr. Hughes joins Intarcia from Brookside Capital, a multi-billion dollar hedge fund under the Bain Capital umbrella, where he served as a Director, co-managing all public and private healthcare investments. In his new position, Mr. Hughes will report directly to Intarcia Chairman, President and CEO Kurt Graves .

(Logo:  http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

"I've known and respected Owen for many years for three key reasons. The first is his penetrating insights and tenacious 'in-it-to-win-it' spirit that will drive significant progress and results for our patients, our people, and our investors," said Mr. Graves. "The second quality is Owen's leadership, external focus and team-building demeanor that fits perfectly into our culture. Third, he is broadly plugged into where healthcare and technology is going and has built valuable relationships with many key players that will be important for our future success. We are thrilled to have him join our team!"

Mr. Hughes' leadership position is newly created at Intarcia and focuses on strategic planning, business operations, as well as oversight of all strategic transactions and business building collaborations. A primary objective will be to build an exciting pipeline with the Company's proprietary technology platforms. He will also work closely with the marketing team as Intarcia builds out new and forward-looking commercial models that fit the rapidly changing healthcare environment. Mr. Hughes' talents should prove very helpful to the Company during a time of intense strategic opportunity and growth.

Prior to working for Brookside Capital (Bain Capital), Mr. Hughes held steadily advancing positions at premier financial institutions, including Pyramis Global Advisors (a Fidelity Investment Company), Triathalon Fund Management LLC, Ziff Brothers Investments, Merrill Lynch / Morgan Stanley, and PaineWebber Incorporated. He graduated from Dartmouth College with a Bachelor of Arts in History. Mr. Hughes was an avid hockey player, having played varsity hockey at Dartmouth all four years, and received the Rookie of the Year Award in addition to subsequent honors in both sports and academics. He resides in the Boston area with his wife and family.

"It will be invigorating working with Owen, as he is very adept at making insightful choices and strategic investments based on his extraordinary sense of opportunities and where markets are going. But he also has amazing follow-up impact by knowing what has to get done tactically and how to be part of a high-performing team that executes to win," added Mr. Graves. "He's as fast-paced and exciting as the ice hockey he used to play. But he's also a good sportsman who never forgets team dynamics and what the real goal in healthcare is all about – doing good for patients."

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JenaValve Appoints John F. Migliazza, Chief Operating Officer
2. H. D. Smith Specialty Solutions Appoints 20-year Industry Veteran Tim Booth To Executive Vice President, Smith Medical Partners
3. MGC Diagnostics Corporation Appoints Wesley W. Winnekins as Executive Vice President, Finance and Corporate Development; Winnekins will also serve as Chief Financial Officer
4. BioLife Solutions Appoints Rick Stewart To Board of Directors
5. NeuroVive Appoints Chief Operating Officer
6. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
7. Regulus Appoints Mark G. Foletta to its Board of Directors
8. Synteract Appoints Keith Kelson as Chief Financial Officer and Member of Executive Council and Philip Doren, Ph.D., as Vice President, Biometrics
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
11. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):